When will 'Fujinokuni HOPE Oncopanel' be available?

We obtained manufacturing and marketing approval on March 24, 2026. We are currently preparing for insurance coverage, and it is expected to be available at medical institutions promptly after coverage is applied.

What is the difference from other genetic tests?

The key feature is that it was developed based on data from 5,143 Japanese cancer patients. Additionally, it uses matched pair analysis comparing tumor and blood samples, allowing for more precise identification of genetic mutations.

Where can I get the test done?

After insurance coverage, the test can be requested at any of the affiliated medical institutions nationwide that contract with SRL. The actual testing will be conducted by the SRL Shizuoka Cancer Center Joint Testing Organization.

AI News NQ Analysis

Fujirebio Obtains Manufacturing and Sales Approval for Cancer Gene Testing System 'Fujinokuni HOPE OncoPanel'

NQ Score 48/100

N1 Content Completeness 5

AI Summary (NQ-processed)

Fujirebio Inc., part of the H.U. Group, obtained regulatory approval for 'Fujinokuni HOPE OncoPanel,' a cancer genome profiling program. Developed based on data from 5,143 Japanese patients in collaboration with Shizuoka Cancer Center and SRL, this system enables precise diagnosis and personalized treatment by analyzing 410 cancer-related genes.

AI Analysis

Frequently Asked Questions

Q: When will 'Fujinokuni HOPE Oncopanel' be available?: A: We obtained manufacturing and marketing approval on March 24, 2026. We are currently preparing for insurance coverage, and it is expected to be available at medical institutions promptly after coverage is applied.
Q: What is the difference from other genetic tests?: A: The key feature is that it was developed based on data from 5,143 Japanese cancer patients. Additionally, it uses matched pair analysis comparing tumor and blood samples, allowing for more precise identification of genetic mutations.
Q: Where can I get the test done?: A: After insurance coverage, the test can be requested at any of the affiliated medical institutions nationwide that contract with SRL. The actual testing will be conducted by the SRL Shizuoka Cancer Center Joint Testing Organization.